Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Cytimmune Sciences logo — Developing safer more effective therapies that can attack tu...

Cytimmune Sciences

Developing safer more effective therapies that can attack tumors on multiple fronts simultaneously.

Founded 2005 United States Rockville, United States 6 employees Venture round Biotechnology, Health Care +1

General Information

Company Name Cytimmune Sciences
Founded Year 2005
Location United States Rockville, United States
Founders / Decision Makers
Team member
Employees 6
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Cytimmune Sciences. To contact Cytimmune Sciences, visit cytimmune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cytimmune Sciences compare?

A PDF of Cytimmune Sciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cytimmune Sciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cytimmune Sciences

Cytimmune Sciences is a biotechnology company founded in 2005 and headquartered in the United States. The company's slogan, "Developing safer more effective therapies that can attack tumors on multiple fronts simultaneously," encapsulates its mission. Their patented IO+ platform has the potential to revolutionize cancer treatment by addressing up to 85% of all cancers. Through this innovative technology, Cytimmune aims to turn hot tumors cold, remodel the tumor microenvironment, and ultimately eliminate cancer cells. The company recently secured Debt Financing investment on 28 December 2020, indicating a strong financial backing for their groundbreaking work. With its focus on biotechnology, healthcare, and pharmaceuticals, Cytimmune Sciences emerges as a promising player in the ongoing battle against cancer.

Taxonomy: nanomedicine, cancer treatment, tumor microenvironment, drug delivery, clinical trials, oncology, therapeutic development, immunotherapy, biologics, chemotherapy, nanoparticle technology

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing Undisclosed -
28 Dec 2020
Venture Series Unknown Undisclosed -
31 Aug 2015
Venture Series Unknown Undisclosed -
18 Sep 2014
Venture Series Unknown Undisclosed -
15 Apr 2014
Debt Financing Undisclosed -
12 Jan 2010
Series B Undisclosed -
21 Nov 2005

Cytimmune Sciences Alternatives & Competitors

Cytimmune Sciences vs
Sensei Bio
Sensei Bio United States

We follow the immune system’s teachings to discover new treatments that inspire the body to fight ca...

Series B
32 employees
Biotechnology, Health Care
Cytimmune Sciences vs
I-Mab Biopharma
I-Mab Biopharma United States

Transforming Potential into Reality.

Post-IPO Equity
100 employees
Biotechnology, Pharmaceutical
Cytimmune Sciences vs
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. United States

Delivering a cancer-free future

Post-IPO Equity
11 employees
Biotechnology, Health Care

FAQ About Cytimmune Sciences

Developing safer more effective therapies that can attack tumors on multiple fronts simultaneously.
Cytimmune Sciences was founded in 2005.
Cytimmune Sciences is headquartered in Rockville, United States.
Cytimmune Sciences operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on nanomedicine, cancer treatment, tumor microenvironment and drug delivery.
Cytimmune Sciences has approximately 6 employees.
Cytimmune Sciences has completed 6 funding rounds. The latest funding stage is Venture round.
Top alternatives and competitors to Cytimmune Sciences include Sensei Bio, I-Mab Biopharma, TransCode Therapeutics, Inc., BioAtla, Inc., Prescient Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cytimmune Sciences and Sensei Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cytimmune Sciences, https://bouncewatch.com/company/cytimmune-sciences, updated 23 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes